Overview

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies

Status:
Not yet recruiting
Trial end date:
2027-11-19
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 or ORION-13 studies.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals